Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study by Rigacci, L. et al.
ORIGINAL ARTICLE
Clinical characteristics of interim-PET negative patients
with a positive end PET from the prospective HD08-01 FIL study
Luigi Rigacci1,2 & Benedetta Puccini1 & Alessandro Broccoli3 & Manjola Dona4 & Manuel Gotti5 & Andrea Evangelista6 &
Armando Santoro7 & Maurizio Bonfichi5 & Alessandro Re8 & Michele Spina9 & Barbara Botto10 & Alessandro Pulsoni11 &
Chiara Pagani8 & Caterina Stelitano12 & Flavia Salvi13 & Luca Nassi14 & LaraMannelli1 & Sofia Kovalchuk1 &Daniela Gioia6 &
Pier Luigi Zinzani3
Received: 15 April 2019 /Accepted: 6 December 2019
# Springer-Verlag GmbH Germany, part of Springer Nature 2019
Abstract
FDG-positron emission tomography (PET) performed early during therapy in advanced Hodgkin lymphoma patients has been
confirmed as being important for progression-free survival. A group of patients with a negative interim-PET (i-PET) showed a
positive end induction PET (e-PET). The aim of this study was to evaluate the clinical characteristics of patients with a positive e-
PET as a secondary end point of the HD0801 study. A total of 519 patients with advanced-stage de novo Hodgkin lymphoma
received initial treatment and underwent an i-PET. Patients with negative results continued the standard treatment. i-PET negative
patients were then evaluated for response with an e-PET and those patients found to have a positive one were also then given a
salvage therapy. Among 409 i-PET negative, 16 interrupted the therapy, 393 patients were evaluated with an e-PET, and 39 were
positive. Sixteen out of 39 underwent a diagnostic biopsy and 15 were confirmed as HD. Seventeen out of 39 e-PET were
reviewed according to the Deauville Score and, in sixteen, it was confirmed positive (10 DS 5, 6 DS 4). With the exception of
high LDH value at diagnosis (p = 0.01; HR 95% CI 1.18–4.89), no clinical characteristics were significantly different in
comparison with e-PET negative patients. Positive e-PET after a negative i-PET has a worse outcome when compared with i-
PET positive patients salvagedwith therapy intensification. It was not possible to identify clinical characteristics associated with a
positive e-PET.
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Introduction
Pre-treatment prognostic tools for advanced-stage HL disease,
notably the International Prognostic Score (IPS), do not accu-
rately predict which patients will receive benefit from a more
intensive therapy [1].
Recently, several studies have clearly demonstrated the
predictive value of a positron emission tomography (PET)
scan performed after two cycles of doxorubicin, bleomycin,
vinblastine, and dacarbazine (ABVD) chemotherapy (i-PET)
in patients with advanced-stage Hodgkin lymphoma (HL)
[2–7]. It is now clear that the i-PET can be considered a sur-
rogate indicator for chemotherapy sensitivity.
A negative i-PET is associated with a better progression-
free survival (PFS) and a positive one is associated with a
worse PFS.
Approximately 65–70% of patients with advanced-stage
Hodgkin lymphoma (HL) can be cured with six to eight cycles
of ABVD, with or without consolidation radiotherapy on
bulky disease [8, 9]. Escalated bleomycin, etoposide, doxoru-
bicin, cyclophosphamide, vincristine, procarbazine, and pred-
nisone (escBEACOPP) cures around 85% of patients if given
as first-line therapy. However, concerns regarding its acute
toxicity, the possible onset of loss of fertility, and second can-
cers or myeloid neoplasia are limiting factors for its wide-
spread use [10, 12, 13].
Patients with a poor prognosis can be identified according
to their early response to induction treatment, as documented
by an interim-PET evaluation and a response adapted therapy
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may be tailored for these patients. Several trials have recently
been completed (RAPID, HD0801, H10, SWOG S0816,
RATHL, GITIL study) that have confirmed the use of a de-
escalate therapy in patients with a favorable early PET re-
sponse or of an escalate therapy in those who do not respond
well, or to do both [14–22].
A negative i-PET scan is a strong predictor of favorable
outcomes with standard therapy and a long-term progres-
sion-free survival (PFS) rate of approximately 95% has been
consistently shown in patients with advanced-stage HL treated
with ABVDwho display an early PET negativity [2–7]. It was
surprising and disconcerting that some patients with negative
i-PET reveal disease progression with a positive PET at the
end of the induction therapy (e-PET).
Concomitantly with the presentation of the final results of
the phase II part of an Italian multicenter trial (HD0801
EudraCT 2008-002684-14 and NCT 00784537; Early
Salvage With High-Dose Chemotherapy and Stem-Cell
Transplantation in Advanced Stage Hodgkin’s Lymphoma),
conducted in centers adhering to the Italian Lymphoma
Foundation (FIL) [20], we have also analyzed the clinical
and biological characteristics and the outcome of those pa-
tients with a positive e-PET who underwent a salvage treat-
ment, as well as patients with positive i-PETwho were offered
a chemotherapy salvage treatment followed by high-dose che-
motherapy with autologous stem-cell support.
Patients and methods
Study oversight
HD0801 was a multicenter study involving patients with new-
ly diagnosed advanced-stage HL [20]. All patients received
first-line ABVD treatment and underwent an i-PET evalua-
tion. PETscans were interpreted according to Juweid’s criteria
[24], which used mediastinal uptake as a reference. Patients
with a positive i-PET were treated with salvage treatment
consisting of high-dose chemotherapy with a subsequent au-
tologous bone marrow transplantation (ABMT) for those pa-
tients obtaining a complete remission as per protocol. Patients
with negative i-PET continued the planned course of six cy-
cles of ABVD as per protocol. The latter set of patients were
restaged with an e-PET and patients with a negative e-PET
underwent follow-up and the few patients with a positive e-
PET underwent salvage therapy. According to the protocol,
this group of patients was withdrawn from the study and was
evaluated retrospectively.
Patient enrollment and study conduct
Patients aged 18 to 70 years were considered eligible if they
had previously untreated and histologically documented HL
(with the exception of nodular lymphocyte–predominant sub-
type) in clinical stage IIB to IVaccording to Ann Arbor stag-
ing and at least one bidimensionally measurable target lesion
(even if extranodal only). Responses were primarily assessed
by centrally reviewed i-PET scans after two cycles of ABVD
and at the end of the scheduled treatment plan, provided that
all patients had undergone a complete staging workup, includ-
ing PET examination, prior to commencing treatment. In the
protocol was suggested to perform a CT evaluation after 4
cycles of therapy and was mandatory to perform a CT at the
end of therapy. The characteristics of patients with negative i-
PET and negative or positive e-PET are reported in Table 1.
Patients with a positive e-PETwere withdrawn from the study
and the authors were asked to summarize the outcome of these
patients, in particular regarding the possible biopsy of the e-
PET positive nodes and the histological results, and which
other methods were used to exclude a false positivity, the
treatment they performed, and finally the patient’s condition
at the last follow-up. All local ethic committees at each center
approved the study protocol and its amendments, in accor-
dance with Italian law and in compliance with the
Declaration of Helsinki. Patients provided a signed informed
consent before being included in the study.
Central PET review
In the HD0801 study, a central PET review played a pivotal
role in reducing the variability of visual scan interpretation
between various readers, because treatment decisions were
made on the basis of the result of i-PET2 scans. A central
review of all uncertain results took place within 5 days of
the i-PET scan at a central imaging core laboratory at the
University of Florence; a panel of 11 nuclear medicine physi-
cians served as reviewers for all procedures. PET scans were
interpreted according to Juweid’s criteria [24], which used
mediastinal uptake as a reference. During the protocol accrual,
end of therapy FDG-PET scans were reviewed at the discre-
tion of clinicians that was not mandatory during the study.
According to the aim of this study, e-PET scans were
reviewed using the Deauville criteria [25], now regarded as
the standard criteria for PET interpretation. We decided not to
review the i-PET of 39 patients with e-PET positive, because
they were considered negative with Juweid’s criteria and thus
could be also considered negative with the Deauville criteria.
Statistical analysis
The sample size of the phase II part of the trial has been
estimated according to the Fleming-A’Hern design. The pri-
mary efficacy end point was calculated as the cumulative pro-
portion of patients alive and with 2-year progression-free sur-
vival. The PFS for patients with negative e-PETwas adequate-
ly corrected considering the salvage therapy for patients with
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positive e-PET, meaning that we added 4 months to the end of
therapy date for negative e-PETs. In practice, PFS was calcu-
lated from the end of therapy plus 4 months to last follow-up
or death for patients with negative e-PET and from the end of
salvage therapy to last follow-up or death for patients with
positive e-PET. Overall survival was calculated for all patients
from induction therapy start to last follow-up or death.
All other time-to-event end points included in the study
have been estimated using the Kaplan-Meier method.
Baseline patient characteristics were compared according to
i-PET negativity using the Mann-Whitney U test and χ2 test
(or Fisher’s exact test, if appropriate) for continuous variables
and categorical variables, respectively. For the safety analyses,
frequency of toxicities was reported by type and grade accord-
ing to the National Cancer Institute Common Terminology
Criteria for Adverse Events (version 2.0). All analyses were
performed by using STATA version 11.1 (STATA, College
Station, TX).
Table 1 Patients’ characteristics according to e-PET result (N = 395)
Characteristics Negative e-PET Positive e-PET* Total p value
(N = 356) (N = 39) (N = 395)
Median age 33 (26;44) 32 (23;43) 32 (26;44) 0.257
Sex 0.727
Male 193 (54%) 20 (51%) 213 (54%)
Female 163 (46%) 19 (49%) 182 (46%)
IPS ‡ 0.156
0–2 183 (57%) 17 (45%) 200 (56%)
≥ 3 139 (43%) 21 (55%) 160 (44%)
Histology 0.356
HL nodular sclerosis 249 (70%) 33 (85%) 282 (71%)
HL mixed cellularity 57 (16%) 2 (5%) 59 (15%)
HL lymphocyte depletion 8 (2%) 1 (3%) 9 (2%)
HL unspecified 27 (8%) 2 (5%) 29 (7%)
HL lymphocyte rich 15 (4%) 1 (3%) 16 (4%)
Systemic symptoms 0.852
A 124 (35%) 13 (33%) 137 (35%)
B 232 (65%) 26 (67%) 258 (65%)
Abnormal LDH° 104 (29%) 19 (49%) 123 (31%) 0.013
Performance Status 0.77
0 232 (65%) 27 (69%) 259 (66%)
1 101 (28%) 9 (23%) 110 (28%)
2 23 (6%) 3 (8%) 26 (7%)
Stage AA 0.363
II 70 (20%) 7 (18%) 77 (19%)
III 126 (35%) 10 (26%) 136 (34%)
IV 160 (45%) 22 (56%) 182 (46%)
Bulky disease 125 (35%) 17 (44%) 142 (36%) 0.295
Extranodal sites 0.152
0 198 (56%) 17 (44%) 215 (54%)
≥ 1 158 (44%) 22 (56%) 180 (46%)
Bone marrow biopsy § 0.845
Negative 313 (90%) 34 (89%) 347 (90%)
Positive 33 (10%) 4 (11%) 37 (10%)
Monocyte > 0.75 × 109/l 98 (48%) 10 (43%) 108 (47%) 0.709
*Included the two patients progressed before e-PET
‡ 35 (9%) missing data
§ 11 (3%) missing data
° 166 (42%) missing data
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Results
In all, 520 patients who had been enrolled on the study started
ABVD treatment between September 2008 and April 2013 in
50 Italian centers. Of those patients, 512 (99%) underwent an
i-PET scan, 1 patient withdrew consent before the therapy
commenced, and 7 patients interrupted the treatment before
the end of the second ABVD cycle. A total of 395 patients
performed a final PET, of which 356 were PET negative and
39 (10%) were PET positive. Sixteen patients underwent a
biopsy of the PET positive sites, and of these, the site was
positive for Hodgkin in 15 patients, and in 1 patient, it was
negative. Twenty-three patients did not have a biopsy, either
for technical reasons or due to the clinicians’ decision. The
patient with the negative biopsy and another patient did not
start any salvage therapy. They are alive and free from pro-
gression and they were therefore excluded from analysis (false
positive e-PET). Moreover, we included the two patients who
progressed before e-PET and were considered as progression
after i-PET negativity.
A comparison of the clinical characteristics of the 37 e-PET
positive patients, the 2 patients who progressed after the i-PET
negative result and the 356 e-PET negative patients after a i-
PET negative are all reported in Table 1. The median age of
the patients was 33 years (range 18 to 68 years). With the
exclusion of LDH value at diagnosis (p = 0.01; HR 95% CI
1.18–4.89), no other clinical characteristics were significantly
different between the two groups. Furthermore, we evaluated
a biological index retrospectively (value of monocyte count at
diagnosis) and this data did not show a difference between the
two groups either. A multivariate logistic regression model
was used to identify any clinical characteristics possibly asso-
ciated with a prevision of e-PET positivity (Table 2) and only
abnormal LDH value at diagnosis was significantly associated
with a higher probability to have a positive e-PET.
Central FDG-PET revision
Seventeen out of 39 e-PET positive patients (44%) were ret-
rospectively reviewed according to the Deauville criteria.
Sixteen patients were confirmed as positive (10 DS of 5 and
6 DS of 4) by the reviewers; one patient could not be agreed
upon and the case was considered inconclusive.
Response to treatment
All positive e-PET patients but one (who had a rapid progres-
sive disease) performed a CT: in 3 patients was not reported an
enlargement of lymph nodes (all these patients were treated
with radiotherapy), in the other 35 patients was observed an
increment of lymph nodes dimension in comparison with a
CT usually performed after 4 cycles or, in the rare cases who
did not have a CT after 4 cycles, the comparison was made
with the co-registered CT of the PET/CT.
Among the 39 patients, 38 were treated with salvage treat-
ment and 1 patient had a very rapid progression and died.
Among the 38 patients treated with salvage therapy, 23 were
treated with two or three cycles of salvage schemes (IGEVand
BEACOPP) and consolidation with an autologous transplant,
6 were treated with an allogenic transplant after several sal-
vage therapies, 6 were treated either with polychemotherapy
and brentuximab vedotin (BV), and 4 were treated with radio-
therapy alone (Table 3).
Twenty-seven patients obtained a complete remission: 4
were treated with radiotherapy alone, 2 were treated with che-
motherapy and BV, 17 patients were consolidated with an
autologous transplant, and 4 with an allogeneic transplant.
Nine patients had progressive disease (2 allotransplanted)
and died and 3 further patients were lost at follow-up but all
three had active disease.
After a median period of 27 months from enrollment, in-
dependently from the salvage type of therapy, on the basis of
intention-to-treat analysis, the 3-year progression-free survival
and overall survival of these group of patients was 54% (95%
CI, 33 to 71%; Fig. 1a) and 77% (95% CI, 55 to 89%)
respectively.
Table 2 Multivariate logistic regression model to identify e-PET
positive predictors
Odds ratio (95% CI) p
Age (unit increase) 0.98 (0.95 to 1.01) 0.176
Female 1.03 (0.49 to 2.16) 0.944
IPS ≥ 3 1.45 (0.64 to 3.3) 0.37
Histology
HL nodular sclerosis 1 -
HL mixed cellularity 0.36 (0.1 to 1.34) 0.128
HL lymphocyte depletion 0.55 (0.05 to 6.61) 0.637
HL unspecified 0.61 (0.13 to 2.85) 0.528
HL lymphocyte rich 0.54 (0.06 to 4.55) 0.573
B symptoms 0.88 (0.39 to 1.95) 0.744
Abnormal LDH 2.4 (1.18 to 4.89) 0.016
Performance status
0 1 -
1 0.72 (0.31 to 1.68) 0.445
≥ 2 1.08 (0.27 to 4.39) 0.916
Stage AA
II 1 -
III 0.91 (0.3 to 2.78) 0.866
IV 1.51 (0.32 to 7.09) 0.602
Bulky disease 1.23 (0.59 to 2.58) 0.579
Extranodal sites ≥ 1 0.88 (0.24 to 3.27) 0.849
Bone marrow biopsy 0.53 (0.13 to 2.17) 0.377
Monocyte > 0.75 × 109/l 0.71 (0.28 to 1.82) 0.481
Ann Hematol
For the entire population calculated from the trial outset,
after a median follow-up of 27 months from enrollment, the
Kaplan-Meier estimates were 97% (95%CI, 94 to 98%) for 3-
year OS and 80% (95% CI, 76 to 83%) for 3-year PFS.
On the basis of intention-to-treat analysis, after a median
follow-up of 25 months from i-PET scanning, the 3-year PFS
for the negative i-PET patients planned to receive six courses
of ABVD was 81% (95% CI, 76 to 84%), whereas the 3-year
PFS for the positive i-PET patients (n = 101, independently
from the salvage treatment they received) was 76% (95% CI,
66 to 84%). Conversely, the PFS of e-PET positive patients at
36 months was 54% (95% CI, 33 to 71%; see Fig. 1b).
Table 3 Salvage therapy of
patients with i-PET negative and
e-PET positive
Patient Therapy Outcome
1 IGEV, ABMT Death
2 BeGEV, BEACOPP, BV*, allotransplant Death
3 BeGEV, ABMT Alive CR°
4 IGEV, ABMT Alive CR
5 IGEV, ABMT Alive CR
6 IGEV, ABMT Death
7 IGEV, BEACOPP, ABMT, bendamustine BV Death
8 IGEV, ABMT, allotransplant Alive with disease
9 BeGEV Alive CR
10 IGEV, ABMT Alive CR
11 IGEV, BEACOPP, ABMT Death
12 BeGEV, ABMT, BV, allotransplant Alive CR
13 RT^ Alive CR
14 IEV, ABMT, BV Alive CR
15 IEV, ABMT Alive CR
16 IGEV, ABMT Alive CR
17 IGEV Lost to follow-up with active disease
18 IGEV Death
19 IGEV, ABMT Alive CR
20 IGEV, ABMT Alive CR
21 RT Alive CR
22 Unknown Death
23 IGEV, ABMT Lost to follow-up with active disease
24 BV, BEACOPP, bendamustine Alive CR
25 IGEV, ABMT Alive CR
26 IGEV, ABMT Alive CR
27 IGEV, ABMT Alive CR
28 IGEV, BEACOPP, ABMT Alive CR
29 BeGEV, ABMT Alive CR
30 RT Alive CR
31 IGEV, DHAP, ABMT, RT, BV Alive CR
32 IGEV, BV, BEACOPP, ABMT, allotransplant Alive CR
33 RT Alive CR
34 BEACOPP Lost to follow-up with active disease
35 IGEV, ABMT, BV, BEACOPP, bendamustine, allotransplant Death
36 IGEV, BEACOPP, ABMT Alive CR
37 IGEV, ABMT Alive CR
38 IGEV, ABMT Alive CR
39 IGEV, ABMT Death
*BV brentuximab vedotin
^RT radiotherapy
°CR complete remission
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The OS at 36 months for patients was 99% (95% CI, 98 to
100%), 78% (95% CI, 57 to 89%), and 89% (95% CI, 80 to
94%) respectively for i-PET negative/e-PET negative, i-PET
negative/e-PET positive, and i-PET positive (Fig. 2).
Comparing i-PET positive patients who underwent a sal-
vage autologous transplantation (43 patients) and e-PET pos-
itive patients (37), the 3-year OS was respectively 95% (95%
CI, 82 to 98%) and 78% (95% CI, 58 to 90%), and this per-
centage is significantly different (p = 0.02) (Fig. 3).
Discussion
Survival rates for patients with HL, even in advanced stages,
have substantially increased over the last few decades. The
standard first-line is ABVD regimen but with this approach
about 20–25% of patients relapse or show refractoriness [12,
13]. A second-line treatment with high-dose chemotherapy
followed by ABMT is generally reserved for these patients.
An alternative approach consists of trying to cure as many
patients as possible with a more aggressive regimen (i.e., esca-
lated BEACOPP), which should be used from the beginning.
Systematic review and network meta-analysis have shown bet-
ter PFS and OS rates, although this more intense approach
exposes patients to considerable acute and late chemotherapy-
related toxicity [15, 26]. A randomized comparison of ABVD
and BEACOPP in patients with advanced-stage HL has recent-
ly been reported [8, 9] and its results have led some authors to
conclude that initial therapy may not necessarily be highly ag-
gressive in all patients because those who relapse could receive
subsequent intensive salvage therapy. The predictive value of
FDG-PET has been reported in several retrospective studies [3,
4], in particular regarding chemosensitivity when applied after
two or three cycles of ABVD as initial treatment. Recently,
prospective studies have been published in which an i-PETscan
was used to identify those patients not responding to ABVD;
the i-PET positive patients were moved on to a more intensive
Fig. 1 a PFS of 27 patients with positive e-PET treated with salvage
therapy. b PFS of e-PET negative patients (upper line), i-PET positive
patients (median line), and i-PET negative/e-PET positive patients (lower
line)
Fig. 3 Overall Survival for patients with i-PET negative but e-PET
positive (lower line) and patients with i-PET positive salvaged with
early intensified treatment (upper line). p value = 0.02
Fig. 2 Overall survival for patients with i-PET negative/e-PET negative
(upper line), i-PET negative/e-PET positive (lower line), and i-PET
positive (median line)
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treatment regimen. All studies concluded that intensification of
PET2-positive patients increased the 2-year PFS from 12% of
the historical control to more than 65%. Moreover, more than
90% of patients with a negative i-PET, who continued treatment
with ABVD, obtained a complete remission. Themain problem
which confounded clinicians was the observation of a number
of patients who presented a positive e-PET after a negative i-
PET. For this reason, in reconsidering the HD0801 study, we
analyzed those patients who in a prospective study presented a
positive e-PET after a negative i-PET. These patients were con-
sidered as failures after a complete induction therapy and were
treated with salvage therapy. The aim of this retrospective study
in a prospective cohort of consecutively enrolled patients was to
evaluate the clinical or pathological characteristics of these pa-
tients at diagnosis and to compare them with the same charac-
teristics of patients with a negative i-PETand e-PET. Currently,
even if this phenomenon is well known, no significant data are
reported in literature. In the paper by Mesguich et al. [27],
among 23 patients with negative i-PET, 3 had a positive e-
PET and 2 of these patients had treatment failure. The authors
pointed out that the sensitivity of end of treatment FDG-PET is
rather high (80%) although it remains in the range of values
reported in literature [27–30]. Furthermore, the authors con-
firmed the very bad prognosis for patients with a negative i-
PET but a positive e-PET.
We observed 39 patients out 395 patients with negative i-
PETwho then presented a positive e-PET at the end of thera-
py. About half of these patients had a histological biopsy to
confirm the persistence of disease, and in 15 of 16 patients, the
histology results were positive. We succeeded in performing a
retrospective centralized revision of e-PET in 17 patients; in
the remaining patients, it was not possible for technical rea-
sons. The revision according to new Deauville criteria showed
that 16 were positive (Deauville score 4 and 5) and 1 could not
be decided upon by the reviewers. Unfortunately, we did not
find any association of clinical and/or pathological character-
istics and the positive outcome of the PETat the end of therapy
after a promising negative i-PET. The only parameter that
showed a statistical significance in univariate and multivariate
analysis was the elevated value of LDH at diagnosis. This data
could lead one to believe that there was a histological modifi-
cation or an initial diagnostic mistake in particular the possi-
bility to have a composite lymphoma. The revision of diag-
nostic samples and the new biopsies of positive PET nodes,
even if only in half the patients, does not allow us to confirm
this hypothesis. Nevertheless, a biopsy in patients with posi-
tive e-pETshould be considered mandatory to guide the future
program having in mind false positives.
Following recent data that reported a significant asso-
ciation of monocytes count at diagnosis and prognosis, we
analyzed this data in 108 patients, but we did not find any
differences between i-PET negative and e-PET negative
or positive.
The revision of e-PET with Deauville criteria, even if not
performed in all e-PET positive cases, confirms that e-PET
positivity was really a progression of the disease.
Interestingly, patients with negative i-PET but with a pos-
itivity at the end of therapy had a very bad prognosis; these
patients had a worse prognosis in comparison with i-PET pos-
itive patients, intensified with a PFS at 36 months of 76% vs.
54% and an OS at 36 months of 95% vs. 78%. Although
cross-study comparisons cannot be made, at first glance, it
would be notable that this difference, in term of PFS, is con-
firmed in RATHL and SWOG studies [21, 31]. These patients
are those whowe had observed in the past before the use of the
interim-PET and who demonstrated chemo-refractoriness at
the end of the induction therapy (after six or eight ABVD)
and were very difficult to salvage. How novel agents now in
use for HL (i.e., PD-1 blockade) [32] may be able to alter the
natural history of these patients when incorporated into front-
line therapy or used as salvage therapy following i-PET
negative/e-PET positive results will be evaluated in the next
future.
Conclusions
Our study, unfortunately, has not been able to identify clinical
or pathological characteristics at diagnosis that could be useful
to select patients who showed an apparent chemosensitivity,
but who, in reality, were refractory to ABVD. LDH value at
diagnosis was the only parameter associated with a significant
probability to have a positive e-PET. The low number of pa-
tients could account for the lack of identification of more
consistent parameters and for this reason, the collection of
clinical and pathological data of these patients from other
prospective studies could be evaluable in the future.
Moreover, a more accurate histopathological, biological anal-
ysis and more accurate PET evaluation at diagnosis or at in-
terim evaluation (MTVor TLG) could be useful to increase i-
PET specificity to identify those patients who could then have
a positive e-PET. For sure, these data confirm that we cannot
omit FDG-PET at the end of therapy.
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